Conditions: Alcohol Use Disorder (AUD)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 26
Healthy volunteers: no

Brief summary:
The primary hypotheses under test are that alcohol dependent subjects treated with suvorexant will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo. Suvorexant (Belsomra®) received approval by the FDA in 2014 for treatment of insomnia. To control for any effect of pre-existing sleep disturbance for which suvorexant may be indicated, subjects will be stratified on the basis of a Pittsburgh Sleep Quality Index total score of \> 5 versus \<5. Subjects were also stratified by sex.

Detailed description:

Arms:
arm 1: 20 mg single-dose administration given on an inpatient clinical research unit arm 2: Placebo single-dose administration given on an inpatient clinical research unit

Interventions: intervention 1: Suvorexant 20 mg intervention 2: Placebo oral tablet
Intervention descriptions: intervention 1: Single-dose administration of 20 mg suvorexant given on an inpatient clinical research unit intervention 2: Single-dose administration of placebo given on an inpatient clinical research unit

Protocol document:
ICF_002.pdf: 





















Prot_000.pdf: 



































































SAP_001.pdf: